Outcomes of transition from selexipag to parenteral prostacyclin analogues in patients with pulmonary arterial hypertension

Extract Pulmonary arterial hypertension (PAH) remains a progressive, incurable condition often associated with poor outcomes despite advances in therapy [1]. Selexipag, an oral selective prostacyclin receptor agonist, is associated with reduced hospitalisations and slower disease progression when added to an endothelin receptor antagonist (ERA) and/or a phosphodiesterase-5 inhibitor (PDE5i) in patients with PAH [2]. Current recommendations suggest the addition of selexipag for patients with an intermediate–low risk of mortality while receiving ERA/PDE5i therapy [3].